FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112618977> ?p ?o ?g. }

• W2112618977 endingPage "1227" @default.
• W2112618977 startingPage "1213" @default.
• W2112618977 abstract "Fixed-combination intraocular pressure (IOP)-lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP. The aim of this study was to evaluate the safety and efficacy of fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) versus concomitant administration of brinzolamide 1% plus brimonidine 0.2% (BRINZ + BRIM) in patients with open-angle glaucoma or ocular hypertension.This was a prospective, phase 3, multicenter, double-masked, 6-month trial. Patients who had insufficient IOP control with monotherapy or who were receiving 2 IOP-lowering medications were randomized 1:1 to receive twice-daily BBFC or BRINZ + BRIM. IOP was assessed at 9 a.m. and 11 a.m. during week 2, week 6, month 3, and month 6 visits. The primary efficacy endpoint was mean diurnal IOP change from baseline to month 3; noninferiority was concluded if the upper limit of the 95% CI of the between-group difference was <1.5 mmHg. Supportive endpoints included mean IOP, IOP change from baseline, and percentage of patients with IOP <18 mmHg. Adverse events were recorded.The mean diurnal IOP change from baseline with BBFC (least squares mean ± standard error -8.5 ± 0.16 mmHg) was noninferior to that with BRINZ + BRIM (-8.3 ± 0.16 mmHg; mean difference -0.1 mmHg; 95% CI -0.5 to 0.2 mmHg). The upper limits of the 95% CIs were <1.5 mmHg at all time points. Decreases from baseline >8 mmHg were observed for least squares mean diurnal IOP in both groups as early as week 2 and continued to the end of the study. The results of all other supportive endpoints were similar to the primary efficacy endpoint. The most common ocular adverse drug reactions were hyperemia of the eye (reported as ocular or conjunctival hyperemia), visual disturbances, ocular allergic reactions, and ocular discomfort. Common systemic adverse drug reactions included dysgeusia, oral dryness, and fatigue/drowsiness.Brinzolamide 1%/brimonidine 0.2% fixed combination was as well tolerated and effective as concomitant therapy with its components. BBFC reduces treatment burden in patients who require multiple IOP-lowering medications." @default.
• W2112618977 created "2016-06-24" @default.
• W2112618977 creator A5002116092 @default.
• W2112618977 creator A5035706811 @default.
• W2112618977 creator A5039985329 @default.
• W2112618977 creator A5056795063 @default.
• W2112618977 creator A5070145893 @default.
• W2112618977 date "2014-11-28" @default.
• W2112618977 modified "2023-10-14" @default.
• W2112618977 title "Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension" @default.
• W2112618977 cites W1966097749 @default.
• W2112618977 cites W1971217557 @default.
• W2112618977 cites W1974991464 @default.
• W2112618977 cites W1978608810 @default.
• W2112618977 cites W1978986531 @default.
• W2112618977 cites W2002669581 @default.
• W2112618977 cites W2005732438 @default.
• W2112618977 cites W2013270615 @default.
• W2112618977 cites W2015733557 @default.
• W2112618977 cites W2015795073 @default.
• W2112618977 cites W2017591799 @default.
• W2112618977 cites W2022883354 @default.
• W2112618977 cites W2028124768 @default.
• W2112618977 cites W2030694257 @default.
• W2112618977 cites W2030981277 @default.
• W2112618977 cites W2041031004 @default.
• W2112618977 cites W2067119621 @default.
• W2112618977 cites W2068119665 @default.
• W2112618977 cites W2076453446 @default.
• W2112618977 cites W2087041915 @default.
• W2112618977 cites W2101365155 @default.
• W2112618977 cites W2123215356 @default.
• W2112618977 cites W2127263938 @default.
• W2112618977 cites W2140594570 @default.
• W2112618977 cites W2150325002 @default.
• W2112618977 cites W2157904903 @default.
• W2112618977 cites W2162316179 @default.
• W2112618977 cites W2163509101 @default.
• W2112618977 cites W2163815596 @default.
• W2112618977 cites W69428782 @default.
• W2112618977 doi "https://doi.org/10.1007/s12325-014-0168-y" @default.
• W2112618977 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4271137" @default.
• W2112618977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25430900" @default.
• W2112618977 hasPublicationYear "2014" @default.
• W2112618977 type Work @default.
• W2112618977 sameAs 2112618977 @default.
• W2112618977 citedByCount "32" @default.
• W2112618977 countsByYear W21126189772015 @default.
• W2112618977 countsByYear W21126189772016 @default.
• W2112618977 countsByYear W21126189772017 @default.
• W2112618977 countsByYear W21126189772018 @default.
• W2112618977 countsByYear W21126189772019 @default.
• W2112618977 countsByYear W21126189772020 @default.
• W2112618977 countsByYear W21126189772021 @default.
• W2112618977 countsByYear W21126189772022 @default.
• W2112618977 countsByYear W21126189772023 @default.
• W2112618977 crossrefType "journal-article" @default.
• W2112618977 hasAuthorship W2112618977A5002116092 @default.
• W2112618977 hasAuthorship W2112618977A5035706811 @default.
• W2112618977 hasAuthorship W2112618977A5039985329 @default.
• W2112618977 hasAuthorship W2112618977A5056795063 @default.
• W2112618977 hasAuthorship W2112618977A5070145893 @default.
• W2112618977 hasBestOaLocation W21126189771 @default.
• W2112618977 hasConcept C118487528 @default.
• W2112618977 hasConcept C126322002 @default.
• W2112618977 hasConcept C168563851 @default.
• W2112618977 hasConcept C203092338 @default.
• W2112618977 hasConcept C2776521421 @default.
• W2112618977 hasConcept C2778190193 @default.
• W2112618977 hasConcept C2778527774 @default.
• W2112618977 hasConcept C2781092963 @default.
• W2112618977 hasConcept C42219234 @default.
• W2112618977 hasConcept C71924100 @default.
• W2112618977 hasConceptScore W2112618977C118487528 @default.
• W2112618977 hasConceptScore W2112618977C126322002 @default.
• W2112618977 hasConceptScore W2112618977C168563851 @default.
• W2112618977 hasConceptScore W2112618977C203092338 @default.
• W2112618977 hasConceptScore W2112618977C2776521421 @default.
• W2112618977 hasConceptScore W2112618977C2778190193 @default.
• W2112618977 hasConceptScore W2112618977C2778527774 @default.
• W2112618977 hasConceptScore W2112618977C2781092963 @default.
• W2112618977 hasConceptScore W2112618977C42219234 @default.
• W2112618977 hasConceptScore W2112618977C71924100 @default.
• W2112618977 hasIssue "12" @default.
• W2112618977 hasLocation W21126189771 @default.
• W2112618977 hasLocation W21126189772 @default.
• W2112618977 hasLocation W21126189773 @default.
• W2112618977 hasLocation W21126189774 @default.
• W2112618977 hasOpenAccess W2112618977 @default.
• W2112618977 hasPrimaryLocation W21126189771 @default.
• W2112618977 hasRelatedWork W2004167709 @default.
• W2112618977 hasRelatedWork W2012408175 @default.
• W2112618977 hasRelatedWork W2015795073 @default.
• W2112618977 hasRelatedWork W2022883354 @default.
• W2112618977 hasRelatedWork W2030981277 @default.
• W2112618977 hasRelatedWork W2039693834 @default.
• W2112618977 hasRelatedWork W2127356267 @default.
• W2112618977 hasRelatedWork W2137843852 @default.

• next